Components:
Treatment option:
Medically reviewed by Kovalenko Svetlana Olegovna, PharmD. Last updated on 22.03.2022
Attention! Information on this page is intended only for medical professionals! Information is collected in open sources and may contain significant errors! Be careful and double-check all the information on this page!
Treatment of nutritional Vitamin B12 deficiency.
Treatment of vitamin B12 deficiency following partial gastrectomy.
Treatment of tropical sprue, alone or with folic acid.
Treatment of pernicious anaemia when parenteral administration is not possible or not advised.
| Dosage: | Adults: - One or two 5ml spoonfuls of this medicine two or three times daily, or more at the discretion of the physician. Elderly: - The normal adult dose is appropriate for the elderly. Children: - One 5 ml spoonful of this medicine two or three times daily, or more at the disacretion of the physician. |
In pernicious anaemia intramuscular therapy is preferable for initial correction of vitamin B12 deficiency. However, if necessary, the oral route may be used to follow this, in which case at least 300 micrograms should be given daily.
When possible, this medicine doses should be taken between meals.
Method of administration: Oral.
Hypersensitivity to the product.
For pernicious anaemia, an adequate dose must be used and the blood picture must be examined regularly at least every 3 months for 18 months until stabilised, and then annually.
Indiscriminate administration of this medicine may mask the precise diagnosis.
Long term treatment with this medicine may increase the risk of dental carnes. It is important that adequate dental hygiene is maintained.
Medicines containing sugar should be administered with care to patients with Diabetes Mellitus.
None.
Sensitisation to cyancobalamin is rare, but may present as an itching exanthema, and exceptionally as anaphylactic shock.
Acneform and bullous emptions have been reported rarely.
Patients who have become sensitised to Cyanocobalamin bufus by injection are often able to tolerate cyancobalamin by the oral route without trouble.
Reporting of side effects
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard.
Overdosage is unlikely to require treatment.
This medicine contains cyancobalamin vitamin B12, which is used for the treatment of pernicious anaemia, and nutritional deficiencies of vitamin B12 which results in macrocytic anaemia.
The absorption of cobalamins from the gut is dependent upon the glycoprotein intrinsic factor. Cobalamins are transported rapidly into the blood bound to protein, known as transcobalamins. Cobalamins are stored in the liver and excreted in the bile. They are known to cross the placenta.
No further relevant data.
None stated.
None
However, we will provide data for each active ingredient
